(Q45218410)

English

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes

scientific article published in March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

author name string

Adrian S Dobs

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Barry J Goldstein

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Pablo Aschner

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Edward S Horton

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Guillermo E Umpierrez

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Lorraine Duran

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Julie S Hill

7

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Yu Chen

8

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Gregory T Golm

9

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Ronald B Langdon

10

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Debora E Williams-Herman

11

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Keith D Kaufman

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

John M Amatruda

13

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Juan Camilo Arjona Ferreira

14

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

publication date

1 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

Journal of diabetes

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

68-79

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Hypoglycemia: still the limiting factor in the glycemic management of diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Metformin: new understandings, new uses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Rosiglitazone/Metformin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Pioglitazone and metformin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Pathogenesis of NIDDM. A balanced overview

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Differentiating members of the thiazolidinedione class: a focus on safety

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Cardiotoxic drugs: clinical monitoring and decision making

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Regulatory action on rosiglitazone by the U.S. Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1753-0407.2012.00223.X

21 January 2018

Identifiers

10.1111/J.1753-0407.2012.00223.X

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45218410&oldid=2070407289"